CXCR4 and neoplasm: BMS‐936564, a pioneering IgG4 fully human monoclonal antibody, exhibits selective binding affinity to the second extracellular loop of CXCR4. This interaction, pivotal in the context of acute myelogenous leukaemia, instigates a substantial elevation, ultimately triggering apoptosis in tumour cells.